Abstract:Weily Soong, 1 Bradley E Chipps, 2 Warner Carr, 3 Jennifer Trevor, 4 Arpan Patel, 5 Nicole Clarke, 6 Donna D Carstens, 5 Christopher S Ambrose 6 1 AllerVie Health, AllerVie Clinical Research, Birmingham, AL, USA; 2 Capital Allergy & Respiratory Disease Center, Sacramento, CA, USA; 3 Allergy & Asthma Associates of Southern California, Food Allergy Center of Southern California, Mission Viejo, CA, USA; 4 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; 5 BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA; 6 BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA Correspondence: Christopher S Ambrose, BioPharmaceuticals Medical, AstraZeneca, One MedImmune Way, Gaithersburg, MD, 20878, USA, Tel +1 301-398-4454, Email Purpose: Patients living with severe asthma (SA) experience multiple health-related quality of life (HRQoL) impairments. This study examined HRQoL changes after biologic treatment initiation among a large, real-world cohort of patients with SA. Patients and methods: CHRONICLE is an ongoing observational study of subspecialist-treated adults with SA who receive biologics or maintenance systemic corticosteroids or are uncontrolled on high-dosage inhaled corticosteroids with additional controllers. Patients enrolled February 2018–February 2023 were asked to complete the St. George's Respiratory Questionnaire (SGRQ) every 6 months (total score range of 0– 100 [0=best possible health], meaningful change threshold is a 4-unit reduction in the total score). Changes in SGRQ responses from 6 months before initiation to 12 to 18 months after initiation were summarized. Results: A total of 76 patients completed the SGRQ 0 to 6 months before and 12 to 18 months after biologic initiation. The mean (SD) SGRQ total score decreased from 52.2 (20.6) to 41.9 (23.8), with improvement across the symptoms (− 14.5), activity (− 11.0), and impacts (− 8.3) components. For specific impairments reported by ≥ 50% of patients before biologic initiation, fewer reported each impairment after biologic initiation; the largest reductions were for "Questions about what activities usually make you feel short of breath these days [Walking outside on level ground]" (67% to 43%), "Questions about other effects that your respiratory problems may have on you these days [I feel that I am not in control of my respiratory problems]" (55% to 34%), and "Questions about your cough and shortness of breath these days [My coughing or breathing disturbs my sleep]" (63% to 45%). Conclusion: In this real-world cohort of adults with SA, biologic initiation was associated with meaningful improvements in asthma-related HRQoL. These data provide further insight into the burden SA places on patients and the benefits of biologic treatment. Keywords: observational, real-world, health-related quality of life, St. George's Respiratory Questionnaire An estimated 5% to 10% of individuals with asthma have severe asthma (SA), which is defined by the requirement for high-dosage inhaled corticosteroids and additional controllers. 1,2 As compared with the general asthma patient population, patients with SA experience a disproportionately greater burden of symptoms, exacerbations, and treatment requirements, with a commensurate impact on health-related quality of life (HRQoL). 3,4 Patients with persistently uncontrolled SA despite the use of high-dosage inhaled corticosteroids and additional controllers are potential candidates for biologic treatments, which have been shown to reduce asthma exacerbations and the need for oral corticosteroids (OCS) as well as to improve lung function, symptoms, and HRQoL, although specific demonstrated effects vary across biologics. 5 In their treatment preferences and goals, patients with SA may prioritize HRQoL improvements above other outcomes, including the number and severity of exacerbations. 6 Clinical trials and a small number of real-world studies in SA have shown improvements in HRQoL associated with biologic use. 7–15 However, the few real-world studies conducted in the US were treatment-specific and varied in design, patient population, and assessment instruments. 14,15 The impact of biologic treatments as a class on HRQoL in patients with SA in longer-term real-world settings has not been well described. Thus, the objective of this analysis was to examine changes in HRQoL after approximately 1 year of biologic treatment in a broad, real-world sample of US patients with SA. CHRONICLE (ClinicalTrials.gov: NCT03373045) is an ongoing real-world obser -Abstract Truncated-

Understanding patient perception of asthma biologic treatment response

Assessment of asthma control identifies new super responders to anti-IL5r therapy in severe asthma

Exploring Definitions and Predictors of Response to Biologics for Severe Asthma

Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

Exploring Perceptions of Biologic Therapies: A Qualitative Study Among Canadians Living with Severe Asthma

Relationship between knowledge, adherence and self-management with response to monoclonal antibody therapy in patients with severe asthma

Response to Various Biologics in Patients with Both Asthma and Chronic Obstructive Pulmonary Disease

Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma

Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study

Real-world biologics response and super-response in the International Severe Asthma Registry cohort

Association between pre-biologic T2-Biomaker combinations and response to biologics in patients with severe asthma

The Impact of Biological Therapies and the Significance of Their Adherence on Asthma Outcomes

Application Of "Exacto" Scale To Assess Annual Response To Monoclonal Antibodies In Patients With Severe Uncontrolled Asthma.

Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab

[Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice]

"The earlier the better", evolution of Pulmonary Function Tests (PFT) in severe asthma patients treated with Benralizumab after two years.

The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5

Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy

SingleNucleotide Polymorphisms as Biomarkers of Mepolizumab and Benralizumab Treatment Response in Severe Eosinophilic Asthma

A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study

A Longitudinal Retrospective Study Illustrating the Experience of the Pulmonology Clinic of Târgu-Mureș, Romania